Journal of Cancer Policy最新文献

{"title":"The narrow road to expanded access","authors":"H.C. Post , T. Schutte , J. Voortman , I.H. Bartelink , H.W.M. van Laarhoven , M. Crul","doi":"10.1016/j.jcpo.2024.100490","DOIUrl":"10.1016/j.jcpo.2024.100490","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"41 ","pages":"Article 100490"},"PeriodicalIF":1.3,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141288740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global review of COVID-19 mitigation strategies and their impact on cancer service disruptions","authors":"Richa Shah ,&nbsp;Ching Ee Loo ,&nbsp;Nader Mounir Hanna ,&nbsp;Suzanne Hughes ,&nbsp;Allini Mafra ,&nbsp;Hanna Fink ,&nbsp;Ethna McFerran ,&nbsp;Montse Garcia ,&nbsp;Suryakanta Acharya ,&nbsp;Oliver Langselius ,&nbsp;Clara Frick ,&nbsp;Jean Niyigaba ,&nbsp;Nwamaka Lasebikan ,&nbsp;Julia Steinberg ,&nbsp;Richard Sullivan ,&nbsp;Freddie Bray ,&nbsp;André Michel Ilbawi ,&nbsp;Ophira Ginsburg ,&nbsp;Karen Chiam ,&nbsp;Jonathan Cylus ,&nbsp;Isabelle Soerjomataram","doi":"10.1016/j.jcpo.2024.100486","DOIUrl":"10.1016/j.jcpo.2024.100486","url":null,"abstract":"<div><p>During the COVID-19 pandemic, countries adopted mitigation strategies to reduce disruptions to cancer services. We reviewed their implementation across health system functions and their impact on cancer diagnosis and care during the pandemic. A systematic search was performed using terms related to cancer and COVID-19. Included studies reported on individuals with cancer or cancer care services, focusing on strategies/programs aimed to reduce delays and disruptions. Extracted data were grouped into four functions (governance, financing, service delivery, and resource generation) and sub-functions of the health system performance assessment framework. We included 30 studies from 16 countries involving 192,233 patients with cancer. Multiple mitigation approaches were implemented, predominantly affecting sub-functions of service delivery to control COVID-19 infection via the suspension of non-urgent cancer care, modified treatment guidelines, and increased telemedicine use in routine cancer care delivery. Resource generation was mainly ensured through adequate workforce supply. However, less emphasis on monitoring or assessing the effectiveness and financing of these strategies was observed. Seventeen studies suggested improved service uptake after mitigation implementation, yet the resulting impact on cancer diagnosis and care has not been established. This review emphasizes the importance of developing effective mitigation strategies across all health system (sub)functions to minimize cancer care service disruptions during crises. Deficiencies were observed in health service delivery (to ensure equity), governance (to monitor and evaluate the implementation of mitigation strategies), and financing. In the wake of future emergencies, implementation research studies that include pre-prepared protocols will be essential to assess mitigation impact across cancer care services.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"41 ","pages":"Article 100486"},"PeriodicalIF":1.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy resources in the Philippines: A 2022 update","authors":"Johanna Patricia A. Canal ,&nbsp;Michelle Ann B. Eala ,&nbsp;Ma. Veronica Pia N. Arevalo ,&nbsp;Edward Christopher Dee ,&nbsp;Henri Cartier S. Co","doi":"10.1016/j.jcpo.2024.100485","DOIUrl":"10.1016/j.jcpo.2024.100485","url":null,"abstract":"<div><h3>Background</h3><p>Cancer is the third leading cause of death in the Philippines. Radiotherapy (RT) is integral to the treatment and palliation of cancer. Therefore, RT resources across the country must be surveyed and optimized.</p></div><div><h3>Methods</h3><p>Online surveys were sent to the heads of all 50 RT facilities in the Philippines. The survey included items regarding the facility itself, personnel, and available services.</p></div><div><h3>Findings</h3><p>The survey had a 98% response rate. 76% of RT facilities in the Philippines are privately owned; 12 are government/public institutions and 8 are academic centers. Over a third are in the National Capital Region; three regions are without a single RT facility. For a population of &gt;110 million, the Philippines has 53 linear accelerators, 125 radiation oncologists, 56 residents, 114 medical physicists, 113 radiation oncology nurses, and 343 radiation therapists. Nine radiation oncology residency programs are active. All facilities are capable of 3D conformal radiotherapy, and 96% are capable of intensity modulated radiotherapy. &lt;30% offer stereotactic radiotherapy, and &lt;50% offer HDR brachytherapy.</p></div><div><h3>Conclusion</h3><p>While there has been significant expansion of RT resources over the years, RT remains inaccessible for many in the Philippines. Urgent investment in training and retaining RT personnel is needed as well. Policy summary: With its current cancer burden, the Philippines needs at least 170 linear accelerators, 300 radiation oncologists, and 150 medical physicists. Public/government cancer centers must be built, with priority given to regions without RT facilities. HDR brachytherapy and stereotactic radiotherapy services must also be expanded. A national RT task force must be created to ensure the quality, availability, and accessibility of RT in the Philippines. Further work exploring payment schemes that improve access to RT and mitigate financial toxicity is needed, as well as integration of radiation oncology providers and health policy experts into national health system decision making.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"41 ","pages":"Article 100485"},"PeriodicalIF":1.3,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authorship characteristics of hematology and oncology education chapters: A comprehensive analysis","authors":"Heba Altarawneh ,&nbsp;Mohammad Manasrah ,&nbsp;Yasemin Al Shanableh ,&nbsp;Arwa Saed Aldien ,&nbsp;Mohannad A. Manasrah ,&nbsp;Safah Khan ,&nbsp;Lina Altarawneh ,&nbsp;Leen Mohammad Al-Kraimeen ,&nbsp;Farah Al Kasaji ,&nbsp;Asalah Alareeki ,&nbsp;Samer Al Hadidi","doi":"10.1016/j.jcpo.2024.100484","DOIUrl":"10.1016/j.jcpo.2024.100484","url":null,"abstract":"<div><h3>Introduction</h3><p>Achieving diversity and equity in healthcare, especially within academic and clinical spheres, poses significant challenges. This study aims to evaluate gender representation, geographical diversity among authors, and disclosure of conflicts of interest (COIs) in educational materials published by the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).</p></div><div><h3>Materials and methods</h3><p>We conducted a comprehensive cross-sectional analysis covering all volumes of ASCO and ASH educational chapters from 2012 to 2022 and 2000 to 2022, respectively. Author data were extracted from the official websites of ASCO and ASH educational books, focusing on names, affiliations, countries of practice, COIs, and publication titles/subjects.</p></div><div><h3>Results</h3><p>Analysis of 2796 articles revealed significant trends in gender representation. Women comprised 44 % of first authors and 38 % of last authors in ASCO educational books, and 39 % of first authors and 39% of last authors in ASH educational books. Notably, there was a marked increase in female first and last authors over time across both ASCO and ASH publications (p &lt; 0.001). Geographical diversity showed disparities, with the majority of authors affiliated with US institutions (72 % of first and last authors). International authors were less represented, with Canada, the UK, and Italy prominent among articles featuring international women authors. A substantial portion of analyzed articles disclosed COIs, mainly research funding, honoraria, and travel expenses.</p></div><div><h3>Discussion</h3><p>Our findings suggest a notable rise in female authorship, potentially reflecting efforts by ASH and ASCO to promote diversity. International authorship remained stable, while COIs were prevalent, primarily involving research funding. Addressing the need for greater international engagement and improving COI reporting quality are crucial to promote inclusivity and transparency in academic publications.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100484"},"PeriodicalIF":1.3,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company” [J. Cancer Pol. 40 (2024) 100473]","authors":"Francesco Ferrara,&nbsp;Maurizio Capuozzo,&nbsp;Roberto Langella,&nbsp;Ugo Trama,&nbsp;Eduardo Nava,&nbsp;Andrea Zovi","doi":"10.1016/j.jcpo.2024.100479","DOIUrl":"10.1016/j.jcpo.2024.100479","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"41 ","pages":"Article 100479"},"PeriodicalIF":2.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213538324000134/pdfft?md5=48244abdc80016cda2c858510cb39ebb&pid=1-s2.0-S2213538324000134-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sugar tax in Poland – Bittersweet lessons three years after implementation","authors":"Paweł Koczkodaj ,&nbsp;Irmina Maria Michalek","doi":"10.1016/j.jcpo.2024.100483","DOIUrl":"10.1016/j.jcpo.2024.100483","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"41 ","pages":"Article 100483"},"PeriodicalIF":1.3,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular profiling of brain tumors in LMICs: Achievable or impossible?","authors":"Hammad Atif Irshad ,&nbsp;Taha Shaikh ,&nbsp;Muhammad Shakir ,&nbsp;Ahmed Gilani","doi":"10.1016/j.jcpo.2024.100481","DOIUrl":"https://doi.org/10.1016/j.jcpo.2024.100481","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100481"},"PeriodicalIF":1.3,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140816072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company” J. Cancer Policy. 40 (2024) 100473","authors":"Francesco Ferrara ,&nbsp;Maurizio Capuozzo ,&nbsp;Roberto Langella ,&nbsp;Ugo Trama ,&nbsp;Eduardo Nava ,&nbsp;Andrea Zovi","doi":"10.1016/j.jcpo.2024.100480","DOIUrl":"10.1016/j.jcpo.2024.100480","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"41 ","pages":"Article 100480"},"PeriodicalIF":2.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213538324000146/pdfft?md5=8f5791b17a84ea7afdad2d4ba8d00080&pid=1-s2.0-S2213538324000146-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding breast cancer patient pathways and their impact on survival in Mexico","authors":"Fatin Izzati Ramli ,&nbsp;Praveen Thokala ,&nbsp;Thaison Tong ,&nbsp;Karla Unger-Saldaña","doi":"10.1016/j.jcpo.2024.100482","DOIUrl":"10.1016/j.jcpo.2024.100482","url":null,"abstract":"<div><h3>Background</h3><p>Understanding patient pathways from discovery of breast symptoms to treatment start can aid in identifying ways to improve access to timely cancer care. This study aimed to describe the patient pathways experienced by uninsured women from detection to treatment initiation for breast cancer in Mexico City and estimate the potential impact of earlier treatment on patient survival.</p></div><div><h3>Methods</h3><p>We used process mining, a data analytics technique, to create maps of the patient pathways. We then compared the waiting times and pathways between patients who initially consulted a private service versus those who sought care at a public health service. Finally, we conducted scenario modelling to estimate the impact of early diagnosis and treatment on patient survival.</p></div><div><h3>Results</h3><p>Our study revealed a common pathway followed by breast cancer patients treated at the two largest public cancer centres in Mexico City. However, patients who initially sought care in private clinics experienced shorter mean wait times for their first medical consultation (66 vs 88 days), and diagnostic confirmation of cancer (57 vs 71 days) compared to those who initially utilized public clinics. Our scenario modelling indicated that improving early diagnosis to achieve at least 60% of patients starting treatment at early stages could increase mean patient survival by up to two years.</p></div><div><h3>Conclusion</h3><p>Our study highlights the potential of process mining to inform healthcare policy for improvement of breast cancer care in Mexico. Also, our findings indicate that reducing diagnostic and treatment intervals for breast cancer patients could result in substantially better patient outcomes.</p></div><div><h3>Policy summary</h3><p>This study revealed significant differences in time intervals along the pathways of women with breast cancer according to the type of health service first consulted by the patients: whether public primary care clinics or private doctors. Policies directed to reduce these inequities in access to timely cancer care are desperately needed to reduce socioeconomic disparities in breast cancer survival.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100482"},"PeriodicalIF":1.3,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of FDA’s marketing authorization of hereditary cancer testing","authors":"David J. Benjamin ,&nbsp;Mark P. Lythgoe ,&nbsp;Arash Rezazadeh Kalebasty","doi":"10.1016/j.jcpo.2024.100478","DOIUrl":"https://doi.org/10.1016/j.jcpo.2024.100478","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100478"},"PeriodicalIF":1.3,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140632659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}